Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Audere, Medical Diagnostech, Nexstim, Royal Philips.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Allogene, Antengene, Atyr, Immutep, In3bio, Intellia, Pharmazz, Quoin, Samsung Bioepis, Selecta, Servier, TG, Tracon.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Abivax, Amarin, Cocrystal, Confo, Excellthera, Gan & Lee, Geovax, Incannex, IQ-AI, Moderna, Passage, Pipeline, Redx, Transcenta, Venatorx.
Disagreement over offsets for an additional $15.6 billion in COVID-19 funding forced the supplemental pandemic funds recently requested by the White House to be cut from the fiscal 2022 spending bill, so the U.S. House would have the votes to pass the $1.5 trillion omnibus spending package late March 9.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: 7 Hills, Acadia, Altamira, Antengene, Bayer, Biomind, C4, Merck & Co., Orion.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adiso, Aeterna, Astellas, Calcimedica, Cellevolve, Cerveau, Cipher, Depymed, Domain, Erasca, Explicyte, Genetic Leap, Lilly, Roche, Sun.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aim Immunotech, Amryt, Denali, Freeline, Hansa, Novamind, Pfizer, Sobi.
The Biden administration sees the $15.6 billion just provided by Congress as inadequate funding for the pandemic, particularly given the administration’s new test-to-treat initiative, and will continue to press Congress for the remaining $6.9 billion requested by the White House, said Tom Inglesby, senior advisor for the White House COVID response team, at the American Clinical Laboratory Association annual meeting.
RSS
